论文部分内容阅读
目的 :探讨低分子量肝素治疗不稳定型心绞痛 ( U AP)的疗效。方法 :将 87例 U AP患者随机分组 :A组 ( 4 3例 )给予抗心绞痛药物治疗加皮下注射低分子量肝素 0 .4ml( 10 0 0 0 Xa ICU) ,连续 7天 ;B组 ( 4 4例 )仅给予常规抗心绞痛药物治疗。结果 :A组和 B组住院 7天显效率、心肌缺血次数、缺血总负荷、再发心绞痛率、非致死性心肌梗死、心性死亡分别为 74.4%、13 .1± 5 .2、169.8± 49.7、11.6%、2 .3 %、0和 5 0 .0 %、3 2 .3± 5 .4、5 12 .3± 92 .4、3 4 .1%、15 .9%、9.6%。 A组中仅 3例发生皮下瘀斑。结论 :表明 UAP患者用低分子量肝素治疗有效、安全和便利。
Objective: To investigate the efficacy of low molecular weight heparin in the treatment of unstable angina pectoris (UAP). Methods: A total of 87 UAP patients were randomly divided into group A (43 cases) and anti-angina drug treatment (subcutaneous injection of low molecular weight heparin 0.4 ml (10 000 Xa ICU) for 7 days, group B (44 Cases) only given conventional anti-anginal drug therapy. Results: In group A and group B, the effective rate of hospitalization for 7 days, the number of myocardial ischemia, the total ischemic load, the rate of recurrent angina, non-fatal myocardial infarction and cardiac death were 74.4%, 13.1 ± 5.2, 169.8 ± 49.7, 11.6%, 2.3%, 0 and 5.0%, 3 2 .3 ± 5 .4, 5 12 .3 ± 92 .4, 34.1%, 15.9%, 9.6% . Subcutaneous ecchymoses occurred in only 3 cases in group A. CONCLUSIONS: It has been shown that low molecular weight heparin is effective, safe and convenient for UAP patients.